The Board's Role in IPO Readiness
Companies tend to experience an IPO as a financing event: a way to raise capital on better terms than the private markets offer, with a defined process, a bank, a document, and a date. Boards often engage with it in that register, treating readiness as a checklist that counsel and the CFO will work through in the months before filing.
That framing misses what actually happens. An IPO does not merely change where the company's capital comes from. It changes what the board is. A private clinical-stage board is accountable to a small number of known investors who sit at the table, receive information continuously and informally, and can be called on a Sunday. A public board is accountable to a diffuse, largely anonymous shareholder base it will never meet, communicates through regulated channels on defined timetables, and operates under standards of independence, committee structure, and financial reporting that the private company almost certainly did not meet.
The work of becoming that second kind of board is substantial, and most of it cannot be compressed into the quarter before filing. This article is about what the transformation actually requires, what the board specifically owns, and — because this is where companies reliably get hurt — what tends to be left too late.
(This article is governance guidance rather than legal or accounting advice. Listing standards and securities regulations change, apply differently by exchange and issuer status, and require qualified counsel and auditors in any live process.)
Start Earlier Than Feels Necessary
The single most useful thing a board can internalize is that IPO readiness is a posture, not a project. The governance changes that matter — recruiting independent directors, building financial reporting capability, cleaning up related-party arrangements, establishing the discipline of accurate periodic reporting — take quarters to accomplish and longer to season. A board that begins this work twelve to eighteen months before a contemplated offering is working at a comfortable pace. A board that begins three months out is making rushed decisions about permanent things.
There is a further argument for starting early that has nothing to do with the IPO itself. Nearly everything on the readiness list — independent oversight, reliable financial reporting, clean related-party dealings, disciplined disclosure — makes the company better run and more attractive in any exit scenario, including an acquisition. The work is not wasted if the window closes and the company sells instead, which means it can be undertaken without first committing to a path.
Board Composition and the Phase-In Trap
Public listing standards require a degree of board independence that most venture-backed biopharma boards do not have. A five-seat board composed of the CEO, two or three investor designees, and perhaps a founder is a normal private configuration and an inadequate public one. The company will need genuinely independent directors, and it will need them in specific places — particularly on the audit committee, where independence requirements are strictest.
Here is where a technical accommodation becomes a governance trap. A company listing in connection with its IPO is permitted to phase in compliance with the independent committee requirements rather than satisfy them all at once: one independent member at the time of listing, a majority within ninety days of listing, and all members within one year. Nasdaq applies a comparable phase-in to its three-member minimum for the audit committee. These accommodations exist for good reason, and companies routinely and properly rely on them.
The trap is treating the phase-in as permission to defer recruiting. A board that lists with one qualified independent audit committee member and a vague plan to find two more is committing to complete a difficult search on a regulatory clock, while simultaneously absorbing the demands of being newly public. Good independent directors — particularly ones with genuine financial expertise who also understand clinical-stage biopharma — are scarce, take months to identify and recruit, and will not join a company whose process feels desperate. The phase-in is a cushion for timing mismatches, not a substitute for having done the search. Boards should be recruiting toward full compliance well before listing and using the phase-in only for the gaps that remain.
The related composition question is who leaves or steps back. Investor designees hold their seats through arrangements tied to preferred stock that typically converts at the IPO, and the rights that produced those seats generally fall away. Some investor directors will stay on as regular directors; some should not. That conversation is far easier to have twelve months ahead, as a planned evolution, than in the weeks before a filing when it feels like a judgment on the individual.
Financial Reporting Is the Long Pole
If board composition is the most visible readiness gap, financial reporting capability is usually the deepest. Private clinical-stage companies frequently run with a lean finance function that has never produced reporting on a public timetable or to a public standard. Becoming public means quarterly and annual filings on statutory deadlines, with the CEO and CFO personally certifying the financial statements, supported by internal control over financial reporting that actually functions.
Emerging growth company status, available to most biopharma issuers, provides meaningful accommodation here. An EGC may include two years of audited financial statements rather than three in its IPO registration statement, may file its registration statement confidentially at first, may use scaled executive compensation disclosure, and — most significantly — is exempt from the requirement that its auditor attest to management's assessment of internal control over financial reporting under Section 404(b) of Sarbanes-Oxley. That status runs for up to five years after the IPO, subject to earlier loss on revenue, public float, or debt issuance triggers.
Two things about this deserve board attention. First, the exemption is from the auditor's attestation, not from the underlying obligation: management must still establish and maintain internal control over financial reporting, and executives must still certify the financials. A board that reads EGC status as permission to defer building real controls has misread it, and will discover the gap at an inconvenient moment.
Second, and specific to this industry: most biotechnology companies remain pre-revenue for a decade or more, well past the five-year EGC window. This is a recognized problem in the sector — it has repeatedly prompted legislative proposals to extend the exemption for low-revenue issuers, none of which has become law. The practical consequence is that a clinical-stage company that goes public will, in most cases, face the full auditor attestation requirement while still generating no revenue, at a point when every dollar spent on compliance is a dollar not spent on development. That is a foreseeable future cost, and a board doing its job will have it in view at the time of listing rather than encountering it as a surprise in year five.
The Disclosure Transformation
The change that most often catches clinical-stage boards unprepared is not structural but behavioral: what the company can say, to whom, and when.
A private company controls its narrative. It shares data selectively with investors, manages the timing of announcements to its own advantage, and speaks freely to partners and prospects. A public company operates under selective disclosure rules, quiet periods around offerings, and prescribed timing for material information. Informal habits that were unremarkable — a director updating their fund on trial progress, a CEO previewing results to a favored analyst — become serious problems.
For biopharma specifically, the highest-risk territory is clinical data. Statements about trial results, regulatory prospects, and development timelines are the lifeblood of a clinical-stage company's communication with the market and are also the most common basis for securities litigation against such companies. The pattern is familiar: optimistic characterization of interim or topline results, a subsequent disappointment, and litigation asserting that the earlier statements were misleading. The pressure toward optimism is structural — the stock responds to good news, management believes in the program, and the incentive to present data favorably is constant.
The board's contribution is to insist on disclosure discipline as a governance matter rather than a communications one: that the company has real disclosure controls, that material announcements are reviewed by people whose job is accuracy rather than enthusiasm, and that the characterization of clinical results in press releases and investor materials is defensible against the underlying data. This is the public-market version of a discipline the board should already have — the gap between what a trial showed and how it is described — with the stakes substantially raised.
Committee Architecture and Cleanup
Beyond the audit committee, the company will need compensation and nominating committees meeting applicable independence standards, with charters that reflect what those committees will actually do rather than boilerplate downloaded from a template. Compensation committee members face their own independence requirements, and public-company compensation practice — equity plan design, peer benchmarking, the disclosure of executive pay — differs enough from private practice that the committee should be functioning and experienced before listing rather than learning on the job.
Related-party arrangements deserve early attention because they are ubiquitous in venture-backed companies and awkward in public ones. Consulting agreements with directors or their affiliates, services provided by investor-affiliated entities, founder loans, licenses from academic institutions where a director holds a position, space or staff shared with a related company — all of it will be examined, disclosed, and judged. Some of these arrangements are perfectly appropriate and simply require disclosure. Others should be restructured or terminated. Either way, the board wants to identify and resolve them on its own timetable rather than in response to a diligence question, and it wants a standing process for approving such transactions going forward.
Director and officer insurance also changes materially. Public-company D&O coverage is a different and more expensive product than the private equivalent, and the terms matter to the individuals serving. This is worth addressing before the directors the company is trying to recruit start asking about it, because they will.
What Gets Left Too Late
Across companies, the same items recur as late-stage scrambles.
Independent director recruitment, deferred on the strength of the phase-in, then attempted under time pressure with a shrinking candidate pool.
Finance staffing, where the company discovers three months before filing that the CFO who capably managed a private clinical-stage balance sheet has never run a public reporting cycle, and that hiring a controller and building a reporting function takes longer than the offering timetable allows.
Internal controls, deferred because EGC status seemed to excuse them, then built hastily without the seasoning that makes controls actually reliable.
Related-party cleanup, left until diligence surfaces arrangements that are embarrassing to explain and slow to unwind.
Disclosure discipline, treated as something that begins at listing rather than a practice the organization needs to have internalized before its first material announcement as a public company.
The common thread is that each of these is a capability rather than a document. Capabilities take time to build and time to become dependable, and none of them can be acquired in the window in which the company is also trying to complete an offering.
The Underlying Principle
The board's role in IPO readiness is not to manage the transaction — bankers, counsel, and the CFO will do that. It is to ensure the company is becoming the kind of company that can responsibly be public, and to start that work early enough that it is genuinely accomplished rather than nominally satisfied.
The distinction between accomplished and nominal runs through everything above. A board can list with a minimally compliant audit committee, a finance function that meets its first deadline by heroics, controls that exist on paper, and disclosure practices that have never been tested — and it will have satisfied the requirements. Whether it has actually built a public company's governance is a different question, and it is the one that determines how the next three years go.
The useful reframe is that almost none of this work is IPO-specific. Independent oversight, reliable reporting, clean dealing, and honest disclosure make a company better governed and more valuable whether it lists, sells, or stays private. A board that treats readiness as something worth having for its own sake, rather than a toll paid at the entrance to the public markets, tends to arrive prepared — and keeps the benefit regardless of which path the company ultimately takes.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on licensing, regulatory, and partnership strategy across the pharmaceutical and advanced materials sectors.